Skip to main content

Prophylactic Intraoperative Norepinephrine Infusion during Major Noncardiac Surgery: A Systematic Review and GRADE assessed Meta-analysis

In brief

Prophylactic norepinephrine trims surgical lactate rise by 0.13 mmol/L

Across 11 trials involving 1,688 patients, prophylactic norepinephrine was linked to a slightly smaller rise in lactate, higher blood pressure and possibly less crystalloid use during major noncardiac surgery. Signals for fewer complications were exploratory, and most evidence was low certainty; larger trials are needed to show whether these changes improve patient outcomes.

Journal
Anaesthesia, critical care & pain medicine (Q1)
Published
18 November 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Edward D M Pereira, Abhay Tyagi, Murilo Scapin, Luwa Haidar, Preet Mohinder Singh
PMID
43051536
DOI
10.1016/j.accpm.2026.102004

Why clinicians should know about it

Abstract

INTRODUCTION: Prophylactic norepinephrine infusion has gained increasing attention to prevent intraoperative hypotension during major non-cardiac surgery, but its effect on haemodynamic stability, tissue perfusion, fluid administration, and postoperative outcomes remains uncertain. METHODS: PubMed, Embase, and Cochrane CENTRAL were searched through May 9, 2026 for randomised trials comparing prophylactic norepinephrine with standard reactive management. Outcomes included change in serum lactate, haemodynamic measures, fluid administration, and postoperative outcomes, including complications and mortality. Risk of bias and certainty of evidence were assessed using Cochrane Risk of Bias 2 (RoB 2) and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, respectively. Sensitivity analyses and trial sequential analysis (TSA) were performed. RESULTS: Eleven trials (1688 patients) were included. Prophylactic norepinephrine was associated with a lower rise in lactate (mean difference (MD) -0.13 mmol/L, 95% CI -0.25 to -0.01; P = 0.03; I²=67.2%), higher post-induction mean arterial pressure (MD 10.79 mmHg, 95% CI 5.53 to 16.04; P < 0.01; I²=95.3%), higher postoperative mean arterial pressure (MD 2.78 mmHg, 95% CI 0.63 to 4.92; P = 0.01; I²=69.8%). Prophylactic norepinephrine use was associated with lower crystalloid administration (MD-548.22 mL, 95% CI -1087.16 to -9.28, P = 0.05, I²=99%) although substantial heterogeneity and protocol-driven differences limit interpretation. Exploratory analyses suggested lower incidences of myocardial infarction (RR 0.25, 95% CI 0.06-0.98), pneumonia (RR 0.58, 95% CI 0.36-0.95), and 30 day-surgical site infection (RR 0.63, 95% CI 0.41-0.97). No statistically significant differences were demonstrated for acute kidney injury, atelectasis, length of stay, or mortality. Certainty of evidence was low for most outcomes. TSA indicated insufficient evidence to establish a definitive treatment effect. CONCLUSIONS: Prophylactic norepinephrine was associated with a statistically significant but small reduction in intraoperative lactate rise, higher post-induction and post-operative mean arterial pressures. Postoperative complication findings remain exploratory and require confirmation in adequately powered randomised trials. REGISTRATION: PROSPERO (CRD420261345140).

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.